ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

ClinicalTrials.gov ID: NCT06422143

Public ClinicalTrials.gov record NCT06422143. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Study identification

NCT ID
NCT06422143
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
851 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Nab-paclitaxel Drug
  • Paclitaxel Drug
  • Pembrolizumab Biological
  • sac-TMT Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 9, 2024
Primary completion
Jan 11, 2029
Completion
Feb 11, 2031
Last update posted
Apr 27, 2026

2024 – 2031

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
CARTI Cancer Center ( Site 0006) Little Rock Arkansas 72205 Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122) Burbank California 91505 Recruiting
Exempla Lutheran Medical Center ( Site 0119) Golden Colorado 80401 Recruiting
Intermountain Health St. Mary's Regional Hospital ( Site 0116) Grand Junction Colorado 81501 Recruiting
Mid Florida Hematology and Oncology Center ( Site 0109) Orange City Florida 32763 Completed
Centricity Research Columbus Cancer Center ( Site 0111) Columbus Georgia 31904 Completed
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001) Marietta Georgia 30060 Completed
Southeastern Regional Medical Center ( Site 0004) Newnan Georgia 30265 Recruiting
University of Chicago Medical Center ( Site 0145) Chicago Illinois 60637 Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146) Minneapolis Minnesota 55407 Recruiting
Capital Health Medical Center - Hopewell ( Site 0034) Pennington New Jersey 08534 Recruiting
New Mexico Oncology Hematology Consultants Ltd. ( Site 0123) Albuquerque New Mexico 87109 Completed
University of New Mexico Comprehensive Cancer Center ( Site 0135) Albuquerque New Mexico 87131 Recruiting
St Luke's University Health Network ( Site 0017) Bethlehem Pennsylvania 18015 Recruiting
Thomas Jefferson University - Clinical Research Institute ( Site 0147) Philadelphia Pennsylvania 19107 Recruiting
Memorial Hermann Cancer Center ( Site 0015) Houston Texas 77030 Recruiting
Oncology Consultants P.A. ( Site 0124) Houston Texas 77030 Recruiting
Mays Cancer Center ( Site 0132) San Antonio Texas 78229 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 189 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06422143, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06422143 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →